Brief: Bergenbio's Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For COVID-19

Oncoinvent ASA

28/04/2020 22:46

April 28 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO'S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS
POTENTIAL
TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT
CLINICAL TRIAL INITIATIVE
    * BERGENBIO ASA - BEMCENTINIB SELECTED AS FIRST CANDIDATE TO
BE
TESTED THROUGH NEW ACCORD STUDY
    * BERGENBIO ASA - PHASE II CLINICAL TRIAL INITIATIVE TO
RAPIDLY
INVESTIGATE BEMCENTINIB'S EFFICACY AND SAFETY IN HOSPITALISED
COVID-19 PATIENTS
    * BERGENBIO ASA - STUDY TO BE FUNDED BY UK DEPARTMENT OF
HEALTH
AND SOCIAL CARE AND UK RESEARCH AND INNOVATION

Source text for Eikon:  ID:nWkr6DL3dX 
Further company coverage:  BGBIO.OL 

 ((Reuters.Briefs@thomsonreuters.com;))